Summit Therapeutics/$SMMT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Ticker

$SMMT
Sector
Health
Primary listing
NASDAQ

Employees

159
Headquarters
Miami, United States
Website
www.smmttx.com

SMMT Metrics

BasicAdvanced
$14B
-
-$1.25
-1.14
-

What the Analysts think about SMMT

Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.

Bulls say / Bears say

Summit is in active negotiations with AstraZeneca to license its lung cancer candidate, ivonescimab, in a deal potentially worth up to $15 billion, which could deliver substantial upfront and milestone payments (Reuters).
A global study of ivonescimab is set to report data in mid-2025, potentially paving the way for its first U.S. approval and unlocking significant revenue upside upon positive results (Bloomberg).
Ivonescimab has already secured marketing approval in China (May 2024) and is pending a U.S. filing, reflecting accelerated regulatory progress for Summit’s lead oncology candidate (Reuters).
A late-stage study of ivonescimab combined with chemotherapy showed a positive survival trend but failed to achieve statistical significance, raising concerns about its clinical efficacy (Reuters).
Ivonescimab, despite promising early data in China, remains pending U.S. approval and faces competition from established immunotherapies like Keytruda, which could limit its market penetration (Reuters).
Summit reported a net loss of $614.9 million in 2023, underscoring continued cash burn and dependence on external financing to fund operations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SMMT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SMMT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

SMMT News

AllArticlesVideos
Why Wall Street Is Backing These 3 Comeback Stocks

Why Wall Street Is Backing These 3 Comeback Stocks

MarketBeat2 days ago
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Business Wire1 week ago
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SMMT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs